Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD125
Clinical data
ATC code none
Legal status
Legal status
  • investigational
CAS Number 1044511-01-4 N
ChemSpider none
UNII 71492GE1FX YesY
KEGG D09874 N
Chemical and physical data
Formula C6492H10060N1724O2028S42
Molar mass 146.0 kg/mol
 NYesY (what is this?)  (verify)

Benralizumab (INN) is a monoclonal antibody which is being developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]

Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3]


  1. Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
  2. Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs : the investigational drugs journal. 13 (9): 601–604. PMID 20799138.
  3. AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016

This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.